See every side of every news story
Published loading...Updated

Ozempic carries a weighty risk

  • Research published in JAMA Neurology indicates GLP-1 drugs, like Ozempic, may reduce the risk of dementia in people with type 2 diabetes.
  • The study involved 23 trials and found GLP-1 therapy statistically significant in lowering dementia risk compared to controls.
  • Dr. Daniel Drucker, a recipient of the 2025 Breakthrough Prize, highlighted the impact of GLP-1 medications on various health conditions.
  • Novo Nordisk is conducting trials on semaglutide for early Alzheimer's, aiming to provide more evidence on GLP-1's protective effects.
Insights by Ground AI
Does this summary seem wrong?

15 Articles

All
Left
6
Center
1
Right
1
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources lean Left
75% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pipe Dream broke the news in on Monday, April 7, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.